Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine

European Journal of Pharmaceutical Sciences

Volumn 15, Issue 3, 2002, Pages 243-250

  Vizirianakis, Ioannis S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Biodrugs; Education; Genes; Genomic technologies; Personalized medicine; Pharmacogenomics; Pharmacy

Indexed keywords

DIAGNOSIS; DNA; GENETIC ENGINEERING; MEDICAL EDUCATION;

MOLECULAR TARGETS;

DRUG PRODUCTS;

DIAGNOSTIC AGENT; DNA; RECOMBINANT DNA;

BIOINFORMATICS; BIOTECHNOLOGY; COMBINATORIAL CHEMISTRY; CURRICULUM; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SCREENING; GENE TECHNOLOGY; GENOME; HUMAN; MARKET; MEDICAL EDUCATION; MEDICINE; PHARMACEUTICS; PHARMACIST; PHARMACOGENOMICS; PHARMACY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; TECHNIQUE; VOCATIONAL EDUCATION;

EID: 0036124608     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00013-1     Document Type: Note

References (69)

1. A vision of pharmacists future roles, responsibilities, and manpower needs in the united states
2. Development of novel biomedicine based on genome science
3. Are graduate programs training pharmaceutical scientists to function effectively in the new, highly integrated and globalized pharmaceutical industry?
4. Collaborative drug therapy management by pharmacists
5. Job matching in pharmacy labor markets: a study in four states
6. Implications of the Human Genome Project for Medical Science
7. DNA microarrays in drug discovery and development
8. Drug discovery: a historical perspective
9. Part 1. Quo vadis, biotech?
10. Part 2. Quo vadis, biotech?
11. Impact of genomics on drug discovery and clinical medicine
12. Increased pharmacists/physician collaboration urged by ACP-ASIM
13. The economic contributions of the biotechnology industry in the US economy
14. Pharmacogenomics: translating functional genomics into rational therapeutics
15. Pharmacogenomics: a new approach to individual therapy of hypertension?
16. The genomics of cardiovascular disorders
17. The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies
18. University education of medicinal chemists: comparison of eight countries
19. Education for a biocomplex future
20. Education: the chemistry between academia and industry
21. The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs
22. Why pharmacogenomics? Why now?
23. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
24. Pharmacogenetics: a tool for individualising antineoplastic therapy
25. Applied neurogenomics
26. Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery
27. Exploiting human genetic variation in drug discovery and development
28. HTS in the new millenium: the role of pharmacology and flexibility
29. Proteomics: a technology-driven and technology-limited discovery science
30. Pharmacogenomics of drug transporters: the next drug delivery challenge
31. Pharmacogenetics and pharmacogenomics
32. Interindividual variability in inhibition and induction of cytochrome P450 enzymes
33. Pharmacogenomics of neurodegenerative diseases
34. The use of single-nucleotide polymorphism in pharmacogenomics
35. Pharmacogenomics: unlocking the human genome for better drug therapy
36. Education: the chemistry between academia and industry
37. Pharmacogenetics and adverse drug reactions
38. A suggested postgraduate curriculum for education and training for the biopharmaceutical industry
39. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine
40. Opportunities for medical research in the 21st century
41. Clinical pharmacogenomics: applications in pharmaceutical R&D
42. Will biomedicine outgrow support?
43. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review
44. Nicotine metabolism defect reduces smoking
45. Pharmacogenomics of psychiatric disorders
46. Polymorphisms of CYP2A6 and its practical consequences
47. Pharmacogenetics and the practice of medicine
48. Genomic medicine and the future of health care
49. Pharmacogenomics: implications for laboratory medicine
50. Using bioinformatics in gene and drug discovery
51. Education in pharmaceutical sciences needs a brand new direction to meet the challenges of drug research and development
52. Transcriptional profiling in cancer: the path to clinical pharmacogenomics
53. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy
54. Graduate education in pharmaceutical sciences: how can it better meet the needs of generic pharmaceutical industry?
55. The last hurdle
56. Identification and development of new biopharmaceuticals
57. Pharmacogenomics: will it change the field of medicine?
58. Rationale and design of the LURIC study: a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease
59. The European university as a startup generator
60. The human CYP3A subfamily: practical considerations
61. Molecular basis of ethnic differences in drug disposition and response